Syapse customers treat 1 in 10 cancer patients in the United States.Watch Video
Intermountain Healthcare is widely recognized as a leader in implementing evidence-based medicine. Intermountain and Syapse partnered in July 2013 to launch Intermountain Precision Genomics, an enterprise-wide oncology clinical service that provides genomics-driven treatment planning and drug procurement, while aggregating clinical, genomics, treatment, and outcomes data to support research. Syapse and Intermountain conducted the first clinical utility and cost effectiveness study of precision oncology, which was initially announced at ASCO in 2015 and featured at the White House Precision Medicine Initiative Summit in 2016.Learn More Case Study
Swedish Cancer Institute (SCI) at Providence launched its Personalized Medicine Program to bring genomics-driven treatment to a community setting. Syapse is helping SCI scale this program across the oncology enterprise to integrate large-scale genomic and clinical data into patients’ whole cancer care journey, including prevention, diagnosis, treatment, and survivorship. With Syapse, SCI is pioneering work on clinical trials matching in the community and on outcomes tracking.
The American Society of Clinical Oncology (ASCO) announced the Targeted Agent and Profiling Utilization Registry (TAPUR) study in June 2015. ASCO selected Syapse to automate the matching of patients to treatments based on genomic and clinical profiles, facilitate TAPUR study workflows, and centralize clinical, genomic, treatment, and outcomes data to build an evidence base for understanding the clinical effectiveness of genomically targeted off-label therapies.
UCSF, one of the leading academic medical centers in the United States, has pioneered the development of precision medicine. UCSF partnered with Syapse in 2014 to enable precision medicine-guided diagnosis and treatment in specialties ranging from oncology to infectious diseases.
Syapse software is a key enabling technology for Stanford Cancer Institute’s Cancer Genetics Clinic. Syapse powers the precision oncology program, including tumor profiling performed in-house at the Stanford Molecular Pathology Laboratory as well as Molecular Tumor Board review, trial enrollment, and data sharing.
Cancer Treatment Centers of America (CTCA) has been a leader in providing patients and physicians with precision cancer treatment using advanced genomic testing. CTCA is partnering with Syapse to scale their precision medicine efforts, enabling the comprehensive implementation of best practices for use of molecular testing and targeted therapies, and tracking of patient outcomes across their large, geographically distributed network.
Accelerate Brain Cancer Cure (ABC2) is a venture philanthropy nonprofit organization that drives cutting-edge research and treatments for brain tumors. ABC2 has partnered with Syapse to launch the Allele project, a collaboration with The Broad Institute and Dana-Farber Cancer Institute that will bring clinical tumor whole-exome sequencing to patients at no cost. The Allele project delivers actionable insights to oncologists and patients today while supporting the development of tomorrow’s therapies. By providing real-time data, the platform enables clinicians to better understand which treatments will most likely work for which patients. Learn more about how Syapse powers the INSIGhT basket trial to find therapies for brain tumor patients faster.
Find out how Syapse can help your organization transform the practice of medicine.Request Demo